• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Zealand Pharma

306.00 DKK

+3.45 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.45 %
-1.48 %
+14.09 %
-34.39 %
-37.91 %
-32.21 %
+10.87 %
+51.79 %
+284.91 %

Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.

Read more
Market cap
21.9B DKK
Turnover
122.78M DKK
Revenue
9.21B
EBIT %
75.52 %
P/E
3.34
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
13.8
2026

Interim report Q2'26

12.11
2026

Interim report Q3'26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release4 hours ago

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Zealand Pharma
Regulatory press release6/10/2026, 8:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release6/8/2026, 3:05 PM

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/8/2026, 3:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Regulatory press release6/7/2026, 6:30 PM

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Zealand Pharma
Regulatory press release6/1/2026, 3:00 PM

Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)

Zealand Pharma
HCA Morgenbørs 01/06 - Europa ned på manglende fredsaftale og resten af verden op på AI
Video6/1/2026, 7:16 AM by
Rasmus Køjborg, Michael Friis

HCA Morgenbørs 01/06 - Europa ned på manglende fredsaftale og resten af verden op på AI

I dagens Morgenbørs ser vi ind i blandede futures - Europa ned på manglende fredsaftale, og resten af verden op på AI. Herhjemme bl.a. fokus på Zealand, Genmab, IT konsulenter, Novonesis.

GenmabDanish Aerospace and Defence CompanyZealand PharmaBioMar GroupNovonesisCurasightTrifork GroupNetcompany Group
Regulatory press release5/29/2026, 8:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release5/26/2026, 3:30 PM

Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)

Zealand Pharma
Regulatory press release5/26/2026, 2:00 PM

Resolutions from Zealand Pharma's Extraordinary General Meeting 2026

Zealand Pharma
Regulatory press release5/14/2026, 3:00 PM

Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)

Zealand Pharma
HCA Morgenbørs 07/05 - Fokus på danske regnskaber
Video5/7/2026, 7:24 AM by
Victor Skriver, Michael Friis

HCA Morgenbørs 07/05 - Fokus på danske regnskaber

I dagens Morgenbørs ser vi ind i et positivt futuresmarked, drevet af rygter om, at Iran og USA er ved at nå til enighed. Herhjemme er der endnu en regnskabsdag i vente med regnskaber fra bl.a. Mærsk, Zealand Pharma, GN Store Nord og ChemoMetec.

A.P. Møller - MærskNovo NordiskZealand PharmaChemoMetecGomSpaceGN Store Nord
HCA Redflag - Zealand Pharma Analyse (AI)
Analyst Comment5/7/2026, 7:21 AM

HCA Redflag - Zealand Pharma Analyse (AI)

HCA Redflag - Zealand Pharma Analyse (AI)

Zealand Pharma
Regulatory press release5/7/2026, 5:05 AM

Zealand Pharma - Execution framework for share buy-back program

Zealand Pharma
Regulatory press release5/7/2026, 5:00 AM

Zealand Pharma Announces Financial Results for the First Three Months of 2026

Zealand Pharma
Regulatory press release5/7/2026, 4:55 AM

Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program

Zealand Pharma
Regulatory press release5/1/2026, 1:00 PM

Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026

Zealand Pharma
HCA Morgenbørs 30/04 - Fokus på bl.a.  Zealand, Danske, Carlsberg
Video4/30/2026, 7:39 AM by
Michael Friis

HCA Morgenbørs 30/04 - Fokus på bl.a. Zealand, Danske, Carlsberg

I dagens Morgenbørs ser vi en negativ start på morgen, miksede tech regnskaber og stigende oliepris trækker ned. Herhjemme fokus på bl.a. Zealand, Danske, Carlsberg

Danske BankCarlsbergZealand PharmaFøroya BankiRockwoolNKTGN Store NordDSV
Regulatory press release4/29/2026, 5:01 PM

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

Zealand Pharma
HCA Morgenbørs 28/04 - Tro på en hurtig fredsløsning ramt
Video4/28/2026, 7:16 AM by
Michael Friis

HCA Morgenbørs 28/04 - Tro på en hurtig fredsløsning ramt

I dagens Morgenbørs ser vi et marked uden retning fra morgenstunden, tro på en hurtig fredsløsning ramt. Herhjemme er der fokus på Zealand, Alm Brand, DS Norden, Embla

D/S NordenTormZealand PharmaAlm. BrandEmbla Medical